Impact of targeted drug therapy on the prognosis of non small cell lung cancer patients with different mutations in the epidermal growth factor receptor gene
10.13699/j.cnki.1001-6821.2015.23.009
- VernacularTitle:靶向药物治疗对表皮生长因子受体基因不同位点突变的非小细胞肺癌患者预后影响
- Author:
Zhong-Yu JIANG
1
;
Chun-Xiu HU
;
Xue-Wu LIU
;
Li WANG
;
Qian MIU
Author Information
1. 浙江衢化医院 肿瘤综合治疗中心
- Keywords:
targeted therapy;
non small cell lung cancer;
tyrosine kinase inhibitor
- From:
The Chinese Journal of Clinical Pharmacology
2015;(23):2306-2308
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigated the impact of patients with ad-vanced non small cell lung cancer (NSCLC) treated by the targeted drug tyrosine kinase inhibitor ( EGFR -TKI ) , and the prognosis of the pa-tients with different mutations in the epidermal growth factor receptor ( EGFR) gene.Methods A total of 69 cases of stageⅢb-ⅣNSCLC patients were selected, there were 21 cases of EGFR gene mutation (+) by DNA testing.Among them, there were 11 cases ( 52.4%) with out-side exon 19 mutations ( treatment group I) , 8 cases (38.1%) with out-side exon 21 mutations ( treatment groupⅡ) , 2 cases (9.5%) with out-side exon 20 mutations ( treatment groupⅢ) .Patients in treatment group were treated with standard regimens and oral TKI ( erlotinib hydrochlo-ride, 150 mg, once daily).The patients in control group were only trea-ted with standard treatment.All patients were followed up for 1 to 2 years, and the short -term efficacy and disease control rate were evaluated, and the progression-free survival rate and 1.5 year survival rate were investigated.Results After treatment, effective rate of treatment and control group ( 85.7%, 52.1%) and disease control rate ( 90.5%, 64.6%) had significant difference ( P<0.05 ); the difference of effective rate in three sub groups of treatment group also had statistically significance (72.7%,50.0%, 0%, P <0.05 ) .At follow -up of 1.5 years, the progression -free survival rate (28.6% and 8.3%) and total survival rate ( 47.6%, 16.7%) of treatment and control groups were significant difference, the significant differences were also observed in the three sub-groups in treatment group ( P<0.05).The treatment effect and the prognosis of patients with the exon 19 mutations in treatment group Ⅰ were better. Conclusion Good clinical effect of NSCLC patients with EGFR gene mutations was obtained by the treatment of TKI, but the prognosis of patients with different mutations of EGFR gene was different.
